Diabetes

SAN ANTONIO — A drug for Type 2 diabetes made by Takeda Pharmaceutical taken in the morning prevented the disease from developing in nearly three-quarters of patients who were at risk, according to a new study in the New England Journal of Medicine.

Researchers enrolled 602 patients through the University of Texas Health Science Center San Antonio and seven other centers and administered Actos (pioglitazone) to them, finding that it prevented Type 2 diabetes in 72% of those whose obesity, ethnicity and other factors put them at risk for the disease.

COPENHAGEN — Novo Nordisk said new data showed that its basal insulin analog is just as effective as human basal insulin in Type 1 diabetes patients ages 2 to 5 years.

JACKSONVILLE, Fla., and DEERFIELD, Ill. — The American Association of Clinical Endocrinologists has teamed up with drug maker Takeda to develop an online resource that will be reviewed and evaluated by top medical experts.

AACE and Takeda will offer a compendium of existing reliable resources specific to Type 2 diabetes, divided into various categories (e.g., management, lifestyle and tools) and reviewed by experts to help healthcare professionals guide their patients and caregivers as they attempt to cut through the clutter of the many resources available.

ALEXANDRIA, Va. — The annual "wake-up call" that asks the American public to find out if they are at risk for developing Type 2 diabetes was held Tuesday.

OAKLAND, Calif. — The Association of Asian Pacific Community Health Organizations has introduced a program that aims to reduce the secondary complications of diabetes among specific ethnic groups living with the disease.

AAPCHO said its five-year diabetes program addresses diabetes among vulnerable populations in three Asian-American, Native Hawaiian and other Pacific Islander communities:

FT. LAUDERDALE, Fla. — Nipro Diagnostics, a provider of diabetes monitoring and management products, announced the promotion of Gregg Johnson to SVP consumer healthcare and Lisa Nardi to VP marketing. Both will continue reporting to Scott Verner, Nipro president.

LONDON — With respect to the Type 2 diabetes drug Avandia, British drug maker GlaxoSmithKline has another medical study to worry about.

CHICAGO — The American Association of Diabetes Educators supported new legislation that was passed in the state of Kentucky that required licensure for all diabetes educators.

The licensing requirement, AADE said, will demonstrate and communicate a standard of care and ensure that people have an appropriate comfort level and respect for the discipline.

The bill was signed by Kentucky state governor Steve Beshear on Wednesday.